These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

191 related articles for article (PubMed ID: 22302548)

  • 1. Accelerated cortical atrophy in cognitively normal elderly with high β-amyloid deposition.
    Chételat G; Villemagne VL; Villain N; Jones G; Ellis KA; Ames D; Martins RN; Masters CL; Rowe CC;
    Neurology; 2012 Feb; 78(7):477-84. PubMed ID: 22302548
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-sectional and longitudinal analysis of the relationship between Aβ deposition, cortical thickness, and memory in cognitively unimpaired individuals and in Alzheimer disease.
    Doré V; Villemagne VL; Bourgeat P; Fripp J; Acosta O; Chetélat G; Zhou L; Martins R; Ellis KA; Masters CL; Ames D; Salvado O; Rowe CC
    JAMA Neurol; 2013 Jul; 70(7):903-11. PubMed ID: 23712469
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Beta-amyloid burden in the temporal neocortex is related to hippocampal atrophy in elderly subjects without dementia.
    Bourgeat P; Chételat G; Villemagne VL; Fripp J; Raniga P; Pike K; Acosta O; Szoeke C; Ourselin S; Ames D; Ellis KA; Martins RN; Masters CL; Rowe CC; Salvado O;
    Neurology; 2010 Jan; 74(2):121-7. PubMed ID: 20065247
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional dynamics of amyloid-β deposition in healthy elderly, mild cognitive impairment and Alzheimer's disease: a voxelwise PiB-PET longitudinal study.
    Villain N; Chételat G; Grassiot B; Bourgeat P; Jones G; Ellis KA; Ames D; Martins RN; Eustache F; Salvado O; Masters CL; Rowe CC; Villemagne VL;
    Brain; 2012 Jul; 135(Pt 7):2126-39. PubMed ID: 22628162
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Subjective cognition and amyloid deposition imaging: a Pittsburgh Compound B positron emission tomography study in normal elderly individuals.
    Perrotin A; Mormino EC; Madison CM; Hayenga AO; Jagust WJ
    Arch Neurol; 2012 Feb; 69(2):223-9. PubMed ID: 22332189
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Hippocampal and cortical atrophy in amyloid-negative mild cognitive impairments: comparison with amyloid-positive mild cognitive impairment.
    Ye BS; Seo SW; Kim CH; Jeon S; Kim GH; Noh Y; Cho H; Yoon CW; Kim HJ; Jang EY; Lee J; Kim JH; Chin J; Lee JM; Kim JH; Seong JK; Kim CH; Choe YS; Lee KH; Na DL
    Neurobiol Aging; 2014 Feb; 35(2):291-300. PubMed ID: 24080178
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Independent contribution of temporal beta-amyloid deposition to memory decline in the pre-dementia phase of Alzheimer's disease.
    Chételat G; Villemagne VL; Pike KE; Ellis KA; Bourgeat P; Jones G; O'Keefe GJ; Salvado O; Szoeke C; Martins RN; Ames D; Masters CL; Rowe CC;
    Brain; 2011 Mar; 134(Pt 3):798-807. PubMed ID: 21310725
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Partial-Volume Effect Correction Improves Quantitative Analysis of 18F-Florbetaben β-Amyloid PET Scans.
    Rullmann M; Dukart J; Hoffmann KT; Luthardt J; Tiepolt S; Patt M; Gertz HJ; Schroeter ML; Seibyl J; Schulz-Schaeffer WJ; Sabri O; Barthel H
    J Nucl Med; 2016 Feb; 57(2):198-203. PubMed ID: 26541776
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of beta-amyloid in a frontal cortical brain biopsy specimen and by positron emission tomography with carbon 11-labeled Pittsburgh Compound B.
    Leinonen V; Alafuzoff I; Aalto S; Suotunen T; Savolainen S; Någren K; Tapiola T; Pirttilä T; Rinne J; Jääskeläinen JE; Soininen H; Rinne JO
    Arch Neurol; 2008 Oct; 65(10):1304-9. PubMed ID: 18695050
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Use of T1-weighted/T2-weighted magnetic resonance ratio to elucidate changes due to amyloid β accumulation in cognitively normal subjects.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Takahashi M; Nakagawara J; Iida H; Kishimoto T; Nagatsuka K
    Neuroimage Clin; 2017; 13():209-214. PubMed ID: 28003959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Amyloid Beta-Weighted Cortical Thickness: A New Imaging Biomarker in Alzheimer's Disease.
    Kim CM; Hwang J; Lee JM; Roh JH; Lee JH; Koh JY;
    Curr Alzheimer Res; 2015; 12(6):563-71. PubMed ID: 26027813
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Differential patterns of regional cerebral hypometabolism according to the level of cerebral amyloid deposition in patients with amnestic mild cognitive impairment.
    Jeon SY; Yi D; Byun MS; Choi HJ; Kim HJ; Lee JH; Baek H; Choe YM; Lee Y; Woo JI; Lee DY
    Neurosci Lett; 2016 Oct; 632():104-8. PubMed ID: 27574728
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Comparison of MRI based and PET template based approaches in the quantitative analysis of amyloid imaging with PIB-PET.
    Edison P; Carter SF; Rinne JO; Gelosa G; Herholz K; Nordberg A; Brooks DJ; Hinz R
    Neuroimage; 2013 Apr; 70():423-33. PubMed ID: 23261639
    [TBL] [Abstract][Full Text] [Related]  

  • 14. High amyloid-β deposition related to depressive symptoms in older individuals with normal cognition: a pilot study.
    Yasuno F; Kazui H; Morita N; Kajimoto K; Ihara M; Taguchi A; Yamamoto A; Matsuoka K; Kosaka J; Kudo T; Iida H; Kishimoto T; Nagatsuka K
    Int J Geriatr Psychiatry; 2016 Aug; 31(8):920-8. PubMed ID: 26766490
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Low PiB PET retention in presence of pathologic CSF biomarkers in Arctic APP mutation carriers.
    Schöll M; Wall A; Thordardottir S; Ferreira D; Bogdanovic N; Långström B; Almkvist O; Graff C; Nordberg A
    Neurology; 2012 Jul; 79(3):229-36. PubMed ID: 22700814
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Amyloid PET imaging in patients with mild cognitive impairment: a 2-year follow-up study.
    Koivunen J; Scheinin N; Virta JR; Aalto S; Vahlberg T; Någren K; Helin S; Parkkola R; Viitanen M; Rinne JO
    Neurology; 2011 Mar; 76(12):1085-90. PubMed ID: 21325653
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Follow-up of [11C]PIB uptake and brain volume in patients with Alzheimer disease and controls.
    Scheinin NM; Aalto S; Koikkalainen J; Lötjönen J; Karrasch M; Kemppainen N; Viitanen M; Någren K; Helin S; Scheinin M; Rinne JO
    Neurology; 2009 Oct; 73(15):1186-92. PubMed ID: 19726751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Basal forebrain atrophy correlates with amyloid β burden in Alzheimer's disease.
    Kerbler GM; Fripp J; Rowe CC; Villemagne VL; Salvado O; Rose S; Coulson EJ;
    Neuroimage Clin; 2015; 7():105-13. PubMed ID: 25610772
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cognitive decline and brain volume loss as signatures of cerebral amyloid-beta peptide deposition identified with Pittsburgh compound B: cognitive decline associated with Abeta deposition.
    Storandt M; Mintun MA; Head D; Morris JC
    Arch Neurol; 2009 Dec; 66(12):1476-81. PubMed ID: 20008651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Feru-guard 100M on amyloid-beta deposition in individuals with mild cognitive impairment.
    Matsuyama K; Yamamoto Y; Sora I
    Psychogeriatrics; 2020 Sep; 20(5):726-736. PubMed ID: 32767414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.